Journal: Transfusion Medicine and Hemotherapy
Submission Deadline: December 31, 2025
Hemophilia management has experienced transformative developments over recent years, significantly reshaping clinical practice and patient outcomes. Novel therapeutic approaches, including gene therapy, extended half-life (EHL) factor concentrates, and non-factor therapies, have created unprecedented opportunities for individualized patient care, while simultaneously introducing new clinical and laboratory challenges. Transfusion Medicine and Hemotherapy welcomes submissions of original research articles and comprehensive reviews for an article collection entitled "Hemophilia – Novel Therapies and Clinical Challenges."
This article collection aims to consolidate cutting-edge research, expert insights, and practical guidance addressing the rapidly evolving landscape of hemophilia care. The collection will provide clinicians, laboratory specialists, researchers, and healthcare professionals involved in hemophilia management with critical knowledge and perspectives to navigate the expanding therapeutic options and associated complexities.
We particularly welcome submissions exploring:
- Developments and real-world experiences with gene therapy (clinical outcomes, patient selection, long-term efficacy and safety).
- Clinical integration of EHL factor concentrates (dosing, adherence, pharmacokinetics, economic considerations).
- Innovative non-factor therapies such as bispecific antibodies (e.g., emicizumab), TFPI inhibitors (e.g., marstacimab, concizumab), and antithrombin-targeting therapies (e.g., fitusiran), highlighting mechanisms, implementation, and safety.
- Laboratory diagnostic challenges and innovations for monitoring novel hemophilia treatments.
- Timing and practical approaches for initiating prophylaxis in pediatric hemophilia care, addressing current controversies and emerging evidence.
- Management of aging hemophilia patients, focusing on comorbidities and individualized therapeutic strategies.
By synthesizing state-of-the-art clinical knowledge with emerging research findings, this collection aims to guide informed decision making and enhance patient care quality in hemophilia treatment. Submissions should clearly address the clinical relevance and translational impact of their findings or reviews.
Please select the option “Call for Papers: Hemophilia – Novel Therapies and Clinical Challenges” when submitting your manuscript and mention this Call for Papers in your cover letter.
Article publication is subject to rigorous peer review in line with the journal's editorial policies. Please refer to our author guidelines for further details about the publication conditions.
Karger Publishers has established agreements with consortia and institutions that include full or partial coverage of Article Processing Charges (APC). Corresponding authors can publish Open Access articles at no or reduced cost if they are associated with or employed by one of these universities/institutions.